Johnson & Johnson was ordered by a Texas jury to pay more than $1 billion to patients who claimed the company hid flaws in its Pinnacle artificial hips that had to be surgically removed, in J&J’s second loss linked to the implants.
Officials of J&J’s DePuy unit, which makes the Pinnacle hips, knew the devices were defective, but failed to properly warn doctors and patients about the risk they would fail, the federal jury in Dallas concluded Thursday. The verdict includes more than $30 million in actual damages for the six plaintiffs and more than $1 billion in punitive damages, according to court filings.
J&J still faces almost 9,000 lawsuits accusing the company of mishandling the metal-on-metal hips. J&J stopped selling the devices in 2013 after the U.S. Food and Drug Administration toughened artificial-hip regulations.
At $1.04 billion in damages, it’s the third-largest overall jury award of 2016, according to data compiled by Bloomberg. The largest, for $3 billion, came in June in a breach of contract case brought by Hewlett-Packard Co. against Oracle Corp. The punitive award against J&J was the largest against a company this year, according to Bloomberg data. Such punishment damages are intended to dissuade defendants from continuing sanctioned practices.
“The jury is telling J&J that they better settle these cases soon,” said Mark Lanier, who represented the group of six hip patients who sued J&J and DePuy. “All they are doing by trying more of these cases is driving up their costs and driving the company’s reputation into the mud.”
J&J’s DePuy unit acted appropriately in designing and testing the product, spokeswoman Mindy Tinsley said in a statement. The companies have strong grounds for appeal and remain committed to the long-term defense of the lawsuit allegations, according to the statement.
Lawyers for J&J said U.S. District Judge Ed Kinkeade’s rulings barred J&J from providing “a fair presentation to the jury.”
“Now the appellate court will need to review errors” made by the judge, attorney John Beisner said in an e-mailed statement. The company will ask Kinkeade not to schedule any more trials until the appellate review is completed, he said.
The verdict continues a losing stretch for J&J before U.S. juries. Six of the seven largest product-defect verdicts in the U.S. this year have been against J&J units, including three in lawsuits claiming its talc products cause ovarian cancer.
J&J won the first Pinnacle hip case to go to trial in October 2014 after a jury rejected a Montana woman’s claims that the devices were defective and gave her metal poisoning. In March, a Dallas jury ordered J&J to pay $502 million to a group of five patients who accused the company of hiding defects in the hips. A judge cut that verdict in July to about $150 million.
The Pinnacle devices weren’t covered by New Brunswick, New Jersey-based J&J’s $2.5 billion settlement covering its ASR line of artificial hips. In 2010 J&J recalled 93,000 of those implants worldwide, saying 12 percent failed within five years.
Since the six hip recipients who sued J&J were all California residents, that state’s law governs the handling of punitive damages awarded in the case. California has no cap on punishment awards, so it may be difficult for the company to argue that this part of the verdict should be reduced under state law.
The U.S. Supreme Court has said such bad-conduct awards must be proportional to compensatory damage verdicts that underlie them and has limited punitive verdicts to 10 times a plaintiff’s actual damages.
The company still faces 8,900 suits over Pinnacle hip failures, according to a May filing with the U.S. Securities and Exchange Commission. That figure is up from 8,300 suits the company listed in an October 2015 regulatory filing.
The patients in the cases before Kinkeade alleged their DePuy hips leached cobalt and chromium material into their bloodstreams, leading to the device failures and surgical removal. They claimed J&J officials knew their metal-on-metal design would cause such injuries but pushed ahead with the product to rack up billions of dollars in sales.
The plaintiffs also contend DePuy officials rushed the Pinnacle hips to market with little testing and turned a blind eye to studies that showed metal-on-metal prosthetics posed a deterioration risk for human tissue and bone.
Kinkeade has scheduled another test trial involving claims by 10 hip recipients for September 2017, according to court filings.
Despite its pledge to appeal Thursday’s verdict, J&J shouldn’t wait for an outcome to approach hip patients with settlement offers, said Erik Gordon, a University of Michigan law professor, who teaches classes about how drugs and medical devices are developed and regulated.
“They may think they have good defenses to these claims, but they don’t seem to be working with juries,” Gordon said in an interview Thursday. “There’s no easy way out of these cases now that they have a billion-dollar verdict against them. They better start thinking of how they can settle these claims before the price goes up any more.”
The consolidated case is In Re DePuy Orthopaedics Inc. Pinnacle Hip Implant Products Liability litigation, 11-md-2244, U.S. District Court, Northern District of Texas (Dallas). The lead case in this trial was Andrews v. DePuy Orthopedics, 15-cv-03484-K, U.S. District Court for the Northern District of Texas (Dallas).